Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Next Previous
Trial Profile

Randomized, Double-blind, Phase 3 Study of TAS-102 Plus Best Supportive Care Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tipiracil/trifluridine (Primary)
  • Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms RECOURSE
  • Sponsors Taiho Oncology

    • Most Recent Events

    • 06 Jun 2023 Results of Matching-adjusted indirect treatment comparison assessing the efficacy and safety of sotorasib with standard of care trifluridine/tipiracil and regorafenib as monotherapy treatments using data from NCT01607957, NCT01103323 and NCT03600883 trials, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
    • 07 Jun 2022 Results (n=37) of an analysis assessing overall survival benefit of trifluridine-tipiracil in patients with metastatic colorectal cancer from discovery cohort presented at the 58th Annual Meeting of the American Society of Clinical Oncology
    • 22 Jan 2022 Results of a pooled analysis (NCT02122913, NCT02637687, NCT02576431, NCT01607957 and NCT01103323 )comparing the expected life-years and quality-adjusted life-years for metastatic CRC patients eligible to receive larotrectinib, regorafenib or trifluridine/tipiracil.presented at the 2022 Gastrointestinal Cancers Symposium
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top